Akira Hattesohl
Papers
1
Total Citations
40
H-Index
1
About
Dr. Akira Hattesohl is a leading translational researcher in gynecologic oncology, whose work bridges molecular diagnostics and real-world clinical application. Her primary research focuses on homologous recombination deficiency (HRD) as a critical biomarker in ovarian cancer, particularly its role in guiding targeted therapy strategies. In her landmark 2022 study, cited over 40 times, Dr. Hattesohl evaluated HRD status in a large, real-world cohort of 514 ovarian carcinoma samples using next-generation sequencing. By analyzing BRCA1/BRCA2 mutations alongside 26,523 single-nucleotide polymorphisms, she demonstrated how comprehensive genomic profiling can identify patients most likely to benefit from PARP inhibitor therapies. This work has been instrumental in moving HRD testing from clinical trials into routine diagnostic practice, directly impacting treatment decisions for women with ovarian cancer. Dr. Hattesohl’s research exemplifies the power of integrating large-scale genomic data with patient outcomes, and her contributions continue to shape precision oncology in gynecologic malignancies.
Research Focus
Key Achievements
Top Papers
- 1